Brain Stimulation for Postherpetic Neuralgia: A Randomized Sham-Controlled Trial
Key facts
- Who runs it
- Huazhong University of Science and Technology
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 94 people, planned
- Started
- 20 Jan 2026
- Planned end
- 30 Jul 2026
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- Non-invasive transcranial stimulation
- Sham Non-invasive transcranial stimulation
- Record updated
- 20 January 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Age ≥ 18 years
- Diagnosis of postherpetic neuralgia (PHN) with disease duration ≥ 3 months
- NRS pain score ≥ 4
- Willing to receive the intervention and able to provide written informed consent
Who cannot take part
- Contraindications to electrical stimulation (e.g., intracranial metal implants, cardiac pacemaker)
- History of epilepsy, severe psychiatric disorder, or cognitive impairment
- Pregnant or breastfeeding women
- Unable to comply with the intervention procedures and follow-up assessments
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Pharmacotherapy is the cornerstone of Postherpetic Neuralgia (PHN) management. First-line treatments for PHN include antiviral agents (e.g., acyclovir, valacyclovir, famciclovir, and brivudine), centrally acting antiepileptic drugs (pregabalin and gabapentin), antidepressants (duloxetine and venlafaxine), and peripherally acting sodium-channel blockers (lidocaine patches).
Read full original descriptionShow less
In recent years, substantial progress has been made in the prevention and treatment of PHN, including early and active antiviral therapy (acyclovir, valacyclovir, famciclovir, brivudine, etc.), analgesic therapy (calcium-channel modulators such as pregabalin and gabapentin; tricyclic antidepressants such as amitriptyline; and opioid analgesics), interventional procedures (e.g., radiofrequency modulation and spinal cord stimulation), and vaccination. Nevertheless, clinical outcomes remain unsatisfactory, with the incidence of refractory PHN still exceeding 50%. Adverse effects associated with certain first- and second-line medications (such as antidepressants and anticonvulsants), as well as the potential risk of opioid dependence, markedly reduce treatment adherence. This situation has compelled clinicians to continually seek new and effective therapeutic approaches for PHN.
Non-invasive transcranial stimulation, as an emerging noninvasive neuromodulation technique, enables targeted modulation of deep brain structures. Animal studies have demonstrated that it can noninvasively regulate neuronal firing in deep regions and induce long-term plasticity, while offering relatively high spatial selectivity and tissue penetration. These features suggest broad clinical potential in chronic pain and affective disorders.
The 2 groups in the trial
- Brain Stimulation + Usual CareTreatment being tested
Participants receive brain stimulation in addition to usual pharmacological care for postherpetic neuralgia. Brain stimulation is delivered once daily for 30 minutes for 10 consecutive days.
Treatment: Non-invasive transcranial stimulation
- Sham Stimulation + Usual CareSham treatment, for comparison
Participants receive sham stimulation in addition to usual pharmacological care. Electrodes are applied once daily for 30 minutes for 10 consecutive days; after an initial brief stimulation to mimic sensation, the output is turned off.
Treatment: Sham Non-invasive transcranial stimulation
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Non-invasive Brain Stimulation for Postherpetic Neuralgia: A Prospective, Randomized, Sham-Controlled Study
- Criteria questions
- Built from NCT07352553, who can take part
- Record updated
- 20 January 2026